effect
protect
mice
ebola
viru
challeng
although
ec
valu
vero
cell
high
suggest
vivo
studi
recommend
evalu
antivir
nucleosid
nafamostat
potent
inhibitor
merscov
prevent
membran
fusion
inhibit
infect
ec
cc
si
nitazoxanid
commerci
antiprotozo
agent
antivir
potenti
broad
rang
virus
includ
human
anim
coronavirus
inhibit
lowmicromolar
concentr
ec
cc
si
vivo
evalu
drug
infect
recommend
notabl
two
compound
remdesivir
ec
cc
si
chloroquin
ec
cc
si
potent
block
viru
infect
lowmicromolar
concentr
show
high
si
fig
b
remdesivir
recent
recogn
promis
antivir
drug
wide
array
rna
virus
includ
sarsmerscov
infect
cultur
cell
mice
nonhuman
primat
nhp
model
current
clinic
develop
treatment
ebola
viru
infect
remdesivir
adenosin
analogu
incorpor
nascent
viral
rna
chain
result
prematur
termin
timeofaddit
assay
show
remdesivir
function
stage
post
viru
entri
fig
agreement
put
antivir
mechan
nucleotid
analogu
warren
et
al
show
nhp
model
intraven
administr
mgkg
dose
remdesivir
result
concomit
persist
level
activ
form
blood
confer
protect
ebola
viru
infect
data
show
ec
valu
remdesivir
vero
cell
suggest
work
concentr
like
achiev
nhp
preliminari
data
supplementari
inform
fig
show
remdesivir
also
inhibit
viru
infect
effici
human
cell
line
human
liver
cancer
cell
sensit
chloroquin
widelyus
antimalari
autoimmun
diseas
drug
recent
report
potenti
broadspectrum
antivir
drug
chloroquin
known
block
viru
infect
increas
endosom
ph
requir
viru
cell
fusion
well
interf
glycosyl
cellular
receptor
sarscov
timeofaddit
assay
demonstr
chloroquin
function
entri
postentri
stage
infect
vero
cell
fig
besid
antivir
activ
chloroquin
immunemodul
activ
may
synergist
enhanc
antivir
effect
vivo
chloroquin
wide
distribut
whole
bodi
includ
lung
oral
administr
ec
valu
chloroquin
vero
cytotox
drug
vero
cell
measur
assay
left
right
yaxi
graph
repres
mean
inhibit
viru
yield
cytotox
drug
respect
experi
done
triplic
b
immunofluoresc
microscopi
viru
infect
upon
treatment
remdesivir
chloroquin
viru
infect
drug
treatment
perform
mention
h
pi
infect
cell
fix
probe
rabbit
sera
np
bat
sarsrel
cov
primari
antibodi
alexa
goat
antirabbit
igg
abcam
secondari
antibodi
respect
nuclei
stain
hoechst
dye
bar
c
timeofaddit
experi
remdesivir
chloroquin
fulltim
treatment
vero
cell
pretreat
drug
h
viru
ad
allow
attach
h
afterward
virusdrug
mixtur
remov
cell
cultur
drugcontain
medium
end
experi
entri
treatment
drug
ad
cell
h
viral
attach
h
pi
virusdrug
mixtur
replac
fresh
cultur
medium
maintain
till
end
experi
postentri
experi
drug
ad
h
pi
maintain
end
experi
experiment
group
cell
infect
moi
viru
yield
infect
cell
supernat
quantifi
qrtpcr
c
np
express
infect
cell
analyz
western
blot
h
pi
cell
clinic
achiev
demonstr
plasma
rheumatoid
arthriti
patient
receiv
mg
administr
chloroquin
cheap
safe
drug
use
year
therefor
potenti
clinic
applic
find
reveal
remdesivir
chloroquin
highli
effect
control
infect
vitro
sinc
compound
use
human
patient
safeti
track
record
shown
effect
variou
ailment
suggest
assess
human
patient
suffer
novel
coronaviru
diseas
